Seegene, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 01:13 am EDT
Share
Seegene, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 84,927.58 million compared to KRW 128,440.42 million a year ago. Net loss was KRW 2,539.56 million compared to net income of KRW 25,150.12 million a year ago. Basic loss per share from continuing operations was KRW 54 compared to basic earnings per share from continuing operations of KRW 494 a year ago. Basic loss per share was KRW 54 compared to basic earnings per share of KRW 494 a year ago.
For the six months, sales was KRW 174,977.43 million compared to KRW 579,892.18 million a year ago. Net loss was KRW 487.62 million compared to net income of KRW 190,622.13 million a year ago. Basic loss per share from continuing operations was KRW 10 compared to basic earnings per share from continuing operations of KRW 3,720 a year ago. Basic loss per share was KRW 10 compared to basic earnings per share of KRW 3,720 a year ago.
Seegene Inc is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The Company provides its products under the brand names of Seeplex, Anyplex and Magicplex. The Company distributes its products within domestic market and to overseas markets.
SEEGENE, INC. 
